title: [Comparison of the Cost-Effectiveness of the SOX and COX Regimens in Patients with Unresectable Advanced and Recurrent Colorectal Cancer Using a Clinical Decision Analysis Approach].
abstract: Phase III clinical trials have comfirmed that the S-1 plus oxaliplatin(SOX)is inferior to the capecitabine plus oxaliplatin (COX)regimen in the treatment of metastatic colorectal cancer.On the basis of these findings, we compared, using a clinical decision analysis-based approach, the cost-effectiveness of the SOX and COX regimens.Herein, we simulated the expected effects and costs of the SOX and COX regimens using the markov model.Clinical data were obtained from Hong's 2012 report.The cost data comprised the costs for pharmacist labor, material, inspection, and treatment for adverse event, as well as the total cost of care at the advanced stage.The result showed that the expected cost of the SOX and COX regimen was 1,538,330 yen, and 1,429,596 yen, respectively, with an expected survival rate of 29.18 months, and 28.63 months, respectively.The incremental cost-effectiveness ratio of the SOX regimen was 197,698 yen/month; thus, the SOX regimen was found to be more cost-effective that the COX regimen.
authors.affiliation: Dept. of Pharmacy, Saiseikai Yokohamashi Tobu Hospital.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nagase
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Iyoda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kanno
authors.forename: Tomohide
authors.initials: T
authors.lastname: Akase
authors.forename: Ichiro
authors.initials: I
authors.lastname: Arakawa
authors.forename: Tadao
authors.initials: T
authors.lastname: Inoue
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Uetsuka
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics* / Q000627:therapeutic use*; D000069287:Capecitabine / Q000008:administration & dosage / Q000191:economics; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000191:economics; D000077150:Oxaliplatin; D010094:Oxonic Acid / Q000008:administration & dosage / Q000191:economics; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000191:economics*; D012008:Recurrence; D005641:Tegafur / Q000008:administration & dosage / Q000191:economics
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000069287:Capecitabine